Business UpdateJun 29, 2026, 08:06 AM
VivoSim Models Show >90% Sensitivity in Liver Toxicity Detection
AI Summary
VivoSim Labs announced that its advanced 3D human tissue models, NAMkind™ Liver and NAMkind™ GI, demonstrated superior predictive power for preclinical safety at a European toxicology conference. The NAMkind™ Liver model achieved over 90% sensitivity in detecting liver toxicity, significantly outperforming animal models (50-65% sensitivity) and reducing false positives to under 5%. These models also accurately predict GI toxicity for both small molecules and complex antibody-drug conjugates (ADCs), aligning with FDA's push for human-relevant alternatives in drug development.
Key Highlights
- VivoSim's NAMkind™ Liver model achieved >90% sensitivity in detecting liver toxicity.
- NAMkind™ Liver model reduced false positives to <5% compared to >10% for current methods.
- The liver model demonstrated 91% predictive accuracy, 90% sensitivity, 95% specificity, and 99% precision.
- VivoSim's models help clients avoid expensive mistakes in drug development, saving $50M - $200M per miss.
- The company's models showed comparable accuracy in testing Antibody Drug Conjugates (ADCs).
- Data was presented at The 23rd International Congress of the European Society of Toxicology In Vitro (ESTIV 2026).
Price Impact
More from VIVS